Table 2.
24-Hour frequency (full analysis set)
| Variable | Placebo (N = 72) | DA-8010 2.5 mg (N = 70) | DA-8010 5 mg (N = 71) | Solifenacin 5 mg (N = 72) |
|---|---|---|---|---|
| Baseline | 11.09 ± 2.58 (10.33) | 10.68 ± 2.34 (10.33) | 10.65 ± 2.12 (10.33) | 10.73 ± 2.03 (10.33) |
| Change from baseline at week 4 | -0.19 ± 2.11 (-0.33) | -0.90 ± 1.68 (-1.00) | -1.38 ± 1.94 (-1.33) | -1.42 ± 2.13 (-1.33) |
| P-value† | 0.0391 | 0.0001 | ||
| Change from baseline at week 8 | -0.78 ± 2.09 (-0.83) | -1.35 ± 1.95 (-1.33) | -1.46 ± 2.18 (-1.33) | -1.28 ± 2.03 (-1.33) |
| P-value† | 0.0335 | 0.021 | ||
| Change from baseline at week 12 | -1.01 ± 2.44 (-1.33) | -1.22 ± 2.05 (-1.33) | -1.67 ± 2.25 (-1.67) | -1.56 ± 2.17 (-1.67) |
| P-value† | 0.2874 | 0.0413 |
Values are presented as mean±standard deviation (median).
The results of the solifenacin 5 mg group were added for exploratory analysis.
†
Rank-analysis of covariance model with adjustment for the baseline value and gender for the comparison of DA-8010 2.5 mg, 5 mg vs. Placebo.